SIMULTANEOUS ESTIMATION OF HYDROCHLORTHIAZIDE AND CANDESARTAN CILEXTIL IN BULK AND PHARMACEUTICAL DOSAGE FORMS BY RP-HPLC PDA METHOD

Hydrochlorothiazide and Candesartan cilextil are used in combination for the treatment of hypertension. The aim of the present investigation was to develop and validate a simple, efficient, economical RP-HPLC method for the simultaneous estimation of Hydrochlorothiazide and Candesartan cilextilin bulk and dosage forms. Chromatographic analysis was performed on Phenomenex C18RP column (250 x 4.6mm; 5µm) with mobile phase containing 10mM ammonium acetate: acetonitrile (65:35% v/v) at a flow rate of 1.2mL/min and eluents were monitored at 262nm. The retention times of Hydrochlorothiazide and Candesartan cilextil were 3.6 min and 6.8 min respectively and showed a good linearity in the concentration range of 7.8-18.8µg/mL for Hydrochlorothiazide and 10-26µg/mL for Candesartan cilextil with a Regression coefficient (R²) of 0.996 and 0.998 respectively. The validation parameters performed were specificity, linearity, limit of detection, limit of quantification, precision, robustness and stability. Validation parameters fulfilled regulatory requirements in all cases. The percentage recoveries ranged in between 98 – 102 (RSD < 2). The RP-HPLC method developed can be successfully used for the simultaneous estimation of Hydrochlorothiazide and Candesartan cilextilin bulk and pharmaceutical dosage forms.